TELEPROM Psoriasis: Enhancing patient-centered care and health-related quality of life (HRQoL) in moderate-to-severe plaque psoriasis

Background and purpose Psoriasis is a chronic, immune-mediated inflammatory skin disease that significantly impacts patients' quality of life. The integration of telepharmacy has the potential to enhance patient care by providing flexible and personalized pharmaceutical follow-up. This study (T...

ver descrição completa

Detalhes bibliográficos
Autores: Mercadal Orfila, Gabriel, López Sánchez, Piedad, Pou Alonso, Aranzazu, Ibarra Barrueta, Olatz, Monte Boquet, Emilio, Borrás Blasco, Joaquin, Padullés Zamora, Nuria, Sanmartin Fenollera, Patricia, Capilla Montes, Cristina, Bernabéu Martínez, M. Ángeles, Herrera Pérez, Salvador
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2024
País:España
Recursos:Universidad de Barcelona
Repositorio:Dipòsit Digital de la UB
OAI Identifier:oai:diposit.ub.edu:2445/219880
Acesso em linha:https://hdl.handle.net/2445/219880
Access Level:acceso abierto
Palavra-chave:Psoriasi
Telecomunicació en medicina
Qualitat de vida
Psoriasis
Telecommunication in medicine
Quality of life
id ES_89eafb6841fdacb0e5a7c93fb6bde0e3
oai_identifier_str oai:diposit.ub.edu:2445/219880
network_acronym_str ES
network_name_str España
repository_id_str
spelling TELEPROM Psoriasis: Enhancing patient-centered care and health-related quality of life (HRQoL) in moderate-to-severe plaque psoriasisMercadal Orfila, GabrielLópez Sánchez, PiedadPou Alonso, AranzazuIbarra Barrueta, OlatzMonte Boquet, EmilioBorrás Blasco, JoaquinPadullés Zamora, NuriaSanmartin Fenollera, PatriciaCapilla Montes, CristinaBernabéu Martínez, M. ÁngelesHerrera Pérez, SalvadorPsoriasiTelecomunicació en medicinaQualitat de vidaPsoriasisTelecommunication in medicineQuality of lifeBackground and purpose Psoriasis is a chronic, immune-mediated inflammatory skin disease that significantly impacts patients' quality of life. The integration of telepharmacy has the potential to enhance patient care by providing flexible and personalized pharmaceutical follow-up. This study (TELEPROM Psoriasis) evaluates a telepharmacy model for evaluating electronic Patient-Reported outcomes (ePROMs) for individuals with moderate to severe plaque psoriasis in Spain with biological treatment.Experimental approach This multicenter prospective quasi-experimental study included 258 adult patients initiating or switching biological/immunomodulatory therapy for moderate to severe plaque psoriasis. Patients were recruited from public hospitals in Spain and monitored through the NAVETA telepharmacy platform over a six-month period. PROMs assessed were the Psoriasis Symptoms and Signs Diary and the Dermatology Life Quality Index at baseline, 1 month, 3 months, and 6 months. Data were analyzed using ANOVA, Student's t-test, multiple regression, and machine learning algorithms to evaluate ePROMs evolution and response and satisfaction with Telepharmacy follow up.Key results The analysis revealed significant influences of gender, employment status, educational level, and daily activity, but no effect of age, on responses to Patient-Reported Outcomes questionnaires. Machine learning models, particularly Random Forest (AUC = 0.98) and Support Vector Machine (AUC = 0.96), effectively predicted patient engagement. DLQI scores significantly decreased from 9.33 +/- 7.75 at baseline to 4.34 +/- 5.86 at 6 months. Similarly, the PSSD - 7 Days questionnaire showed major reductions, with scores dropping from 55.43 +/- 29.94 to 30.73 +/- 30.66 at 6 months, and 53% of patients reaching a score of 20 or less. Notably, women reported worse scores at all time points compared to men. Regression analysis explained only 13.2% of the variance in PROMs scores, identifying Employment Status and BMI Range as key contributors.Conclusion This study demonstrates the efficacy of biologic treatments in significantly improving HRQoL for psoriasis patients. Addressing demographic variables, such as gender, is key for optimizing treatment outcomes and improving ePROMs response rates. Tailored strategies and ML techniques can help identify low-engagement patients and mitigate disparities. Integrating sociodemographic factors into clinical decision-making and patient engagement strategies is fundamental for delivering equitable and comprehensive care.Frontiers Media SA2024info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://hdl.handle.net/2445/219880Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))reponame:Dipòsit Digital de la UBinstname:Universidad de BarcelonaInglésReproducció del document publicat a: https://doi.org/10.3389/fmed.2024.1465725Frontiers in Medicine, 2024, vol. 11https://doi.org/10.3389/fmed.2024.1465725cc-by (c) Mercadal Orfila, Gabriel et al., 2024http://creativecommons.org/licenses/by/3.0/es/info:eu-repo/semantics/openAccessoai:diposit.ub.edu:2445/2198802026-05-27T06:46:51Z
dc.title.none.fl_str_mv TELEPROM Psoriasis: Enhancing patient-centered care and health-related quality of life (HRQoL) in moderate-to-severe plaque psoriasis
title TELEPROM Psoriasis: Enhancing patient-centered care and health-related quality of life (HRQoL) in moderate-to-severe plaque psoriasis
spellingShingle TELEPROM Psoriasis: Enhancing patient-centered care and health-related quality of life (HRQoL) in moderate-to-severe plaque psoriasis
Mercadal Orfila, Gabriel
Psoriasi
Telecomunicació en medicina
Qualitat de vida
Psoriasis
Telecommunication in medicine
Quality of life
title_short TELEPROM Psoriasis: Enhancing patient-centered care and health-related quality of life (HRQoL) in moderate-to-severe plaque psoriasis
title_full TELEPROM Psoriasis: Enhancing patient-centered care and health-related quality of life (HRQoL) in moderate-to-severe plaque psoriasis
title_fullStr TELEPROM Psoriasis: Enhancing patient-centered care and health-related quality of life (HRQoL) in moderate-to-severe plaque psoriasis
title_full_unstemmed TELEPROM Psoriasis: Enhancing patient-centered care and health-related quality of life (HRQoL) in moderate-to-severe plaque psoriasis
title_sort TELEPROM Psoriasis: Enhancing patient-centered care and health-related quality of life (HRQoL) in moderate-to-severe plaque psoriasis
dc.creator.none.fl_str_mv Mercadal Orfila, Gabriel
López Sánchez, Piedad
Pou Alonso, Aranzazu
Ibarra Barrueta, Olatz
Monte Boquet, Emilio
Borrás Blasco, Joaquin
Padullés Zamora, Nuria
Sanmartin Fenollera, Patricia
Capilla Montes, Cristina
Bernabéu Martínez, M. Ángeles
Herrera Pérez, Salvador
author Mercadal Orfila, Gabriel
author_facet Mercadal Orfila, Gabriel
López Sánchez, Piedad
Pou Alonso, Aranzazu
Ibarra Barrueta, Olatz
Monte Boquet, Emilio
Borrás Blasco, Joaquin
Padullés Zamora, Nuria
Sanmartin Fenollera, Patricia
Capilla Montes, Cristina
Bernabéu Martínez, M. Ángeles
Herrera Pérez, Salvador
author_role author
author2 López Sánchez, Piedad
Pou Alonso, Aranzazu
Ibarra Barrueta, Olatz
Monte Boquet, Emilio
Borrás Blasco, Joaquin
Padullés Zamora, Nuria
Sanmartin Fenollera, Patricia
Capilla Montes, Cristina
Bernabéu Martínez, M. Ángeles
Herrera Pérez, Salvador
author2_role author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Psoriasi
Telecomunicació en medicina
Qualitat de vida
Psoriasis
Telecommunication in medicine
Quality of life
topic Psoriasi
Telecomunicació en medicina
Qualitat de vida
Psoriasis
Telecommunication in medicine
Quality of life
description Background and purpose Psoriasis is a chronic, immune-mediated inflammatory skin disease that significantly impacts patients' quality of life. The integration of telepharmacy has the potential to enhance patient care by providing flexible and personalized pharmaceutical follow-up. This study (TELEPROM Psoriasis) evaluates a telepharmacy model for evaluating electronic Patient-Reported outcomes (ePROMs) for individuals with moderate to severe plaque psoriasis in Spain with biological treatment.Experimental approach This multicenter prospective quasi-experimental study included 258 adult patients initiating or switching biological/immunomodulatory therapy for moderate to severe plaque psoriasis. Patients were recruited from public hospitals in Spain and monitored through the NAVETA telepharmacy platform over a six-month period. PROMs assessed were the Psoriasis Symptoms and Signs Diary and the Dermatology Life Quality Index at baseline, 1 month, 3 months, and 6 months. Data were analyzed using ANOVA, Student's t-test, multiple regression, and machine learning algorithms to evaluate ePROMs evolution and response and satisfaction with Telepharmacy follow up.Key results The analysis revealed significant influences of gender, employment status, educational level, and daily activity, but no effect of age, on responses to Patient-Reported Outcomes questionnaires. Machine learning models, particularly Random Forest (AUC = 0.98) and Support Vector Machine (AUC = 0.96), effectively predicted patient engagement. DLQI scores significantly decreased from 9.33 +/- 7.75 at baseline to 4.34 +/- 5.86 at 6 months. Similarly, the PSSD - 7 Days questionnaire showed major reductions, with scores dropping from 55.43 +/- 29.94 to 30.73 +/- 30.66 at 6 months, and 53% of patients reaching a score of 20 or less. Notably, women reported worse scores at all time points compared to men. Regression analysis explained only 13.2% of the variance in PROMs scores, identifying Employment Status and BMI Range as key contributors.Conclusion This study demonstrates the efficacy of biologic treatments in significantly improving HRQoL for psoriasis patients. Addressing demographic variables, such as gender, is key for optimizing treatment outcomes and improving ePROMs response rates. Tailored strategies and ML techniques can help identify low-engagement patients and mitigate disparities. Integrating sociodemographic factors into clinical decision-making and patient engagement strategies is fundamental for delivering equitable and comprehensive care.
publishDate 2024
dc.date.none.fl_str_mv 2024
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/219880
url https://hdl.handle.net/2445/219880
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Reproducció del document publicat a: https://doi.org/10.3389/fmed.2024.1465725
Frontiers in Medicine, 2024, vol. 11
https://doi.org/10.3389/fmed.2024.1465725
dc.rights.none.fl_str_mv cc-by (c) Mercadal Orfila, Gabriel et al., 2024
http://creativecommons.org/licenses/by/3.0/es/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv cc-by (c) Mercadal Orfila, Gabriel et al., 2024
http://creativecommons.org/licenses/by/3.0/es/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Frontiers Media SA
publisher.none.fl_str_mv Frontiers Media SA
dc.source.none.fl_str_mv Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
reponame:Dipòsit Digital de la UB
instname:Universidad de Barcelona
instname_str Universidad de Barcelona
reponame_str Dipòsit Digital de la UB
collection Dipòsit Digital de la UB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869412662961504256
score 15,812455

Registos relacionados